A home-made nano-desorption electrospray ionization (nano-DESI) device and the kinetic method were tested in chiral analysis of model clinical samples containing enantiomers of one of three pharmaceutically important compounds: dihydroxyphenylalanine (DOPA), ephedrine and ibuprofen. The initial evaluation of chiral systems was carried out by direct infusion of solution mixtures (analyte/central metal/chiral reference ligand) to a standard electrospray ionization (ESI) source. Cu(II) was used as a central metal for all analytes, l-phenylalanine was applied as a chiral reference ligand for DOPA, whereas l-tryptophan was used for the other two analytes. Then, the ESI source was substituted by a nano-DESI source and dried spots of 1 μL samples of whole human blood spiked with individual drugs were successfully analyzed without any pre-treatment. Irrespective of a laborious initial nano-DESI set-up, the combination of the kinetic method with nano-desorption electrospray has, for the first time, been demonstrated as a promising tool for chiral analysis of drugs in blood samples.
GrossA., “Best practice in therapeutic drug monitoring”, Brit. J. Clin. Pharmacol.46, 95–99 (1998). doi: 10.1046/j.1365-2125.1998.00770. x
2.
SuthakaranC.AdithanC., “Therapeutic drug monitoring, concepts, methodology, clinical applications and limitations”, Health AdministratorXIX, 22 (2004).
3.
KahanB.D., “A therapeutic drug monitoring of cyclosporine: 20 years of progress”, Transplant. Proc.36, S378–S391 (2004). doi: 10.1016/j.transproceed.2004.01.091
4.
HeeswijkR., “Critical issues in therapeutic drug monitoring of antiretroviral drugs”, Ther. Drug Monit.24, 323–331 (2002). doi: 10.1097/00007691-200206000-00001
5.
EadieM.J., “Therapeutic drug monitoring-antiepileptic drugs”, Brit. J. Clin. Pharmacol.46, 185–193 (1998). doi: 10.1046/j.1365-2125.1998.00769.x
6.
WongS.H.Y.SunshineI., Handbook of Analytical Therapeutic Drug Monitoring and Toxicology.CRC Press, Boca Raton, Florida, USA (1996).
7.
MaurerH.H., “Liquid chromatography–mass spectrometry in forensic and clinical toxicology”, J. Chromatogr. B713, 3–25 (1998). doi: 10.1016/S0378-4347(97)00514-8
8.
ThevisM.ThomasA.DelahautP.BosseloirA.SchänzerW., “Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry”, Anal. Chem.78, 1897–1903 (2006). doi: 10.1021/ac052095z
9.
TakátsZ.GologanB.WisemanJ.M.CooksR.G., “Method and system for desorption electrospray ionization”, US Patent 7,335,897, P1452, (2008).
10.
CooksR.G.OuyangZ.TakatsZ.WisemanJ.M., “Ambient mass spectrometry”, Science311, 1566–1570 (2006). doi: 10.1126/science.1119426
11.
KauppilaT.J.WisemanJ.M.KetolaR.A.KotiahoT.CooksR.G.KostiainenR., “Desorption electrospray ionization mass spectrometry for the analysis of pharmaceuticals and metabolites”, Rapid Commun. Mass Spectrom.20, 387–392 (2006). doi: 10.1002/rcm.2304
12.
TakatsZ.WisemanJ.M.CooksR.G., “Ambient mass spectrometry using desorption electrospray ionization (DESI): Instrumentation, mechanisms and applications in forensics, chemistry, and biology”, J. Mass Spectrom.40, 1261–1275 (2005). doi: 10.1002/jms.922
13.
TakatsZ.WisemanJ.M.GologanB.CooksR.G., “Mass spectrometry sampling under ambient conditions with desorption electrospray ionization”, Science306, 471–473 (2004). doi: 10.1126/science.1104404
14.
WilliamsJ.P.ScrivensJ.H., “Rapid accurate mass desorption electrospray ionisation tandem mass spectrometry of pharmaceutical samples”, Rapid Commun. Mass Spectrom.19, 3643–3650 (2005). doi: 10.1002/rcm.2251
15.
ChenH.TalatyN.N.TakatsZ.CooksR.G., “Desorption electrospray ionization mass spectrometry for high-throughput analysis of pharmaceutical samples in the ambient environment”, Anal. Chem.77, 6915–6927 (2005). doi: 10.1021/ac050989d
16.
WisemanJ.M.IfabD.R.ZhuY.KissingerC.B.ManickeN.E.KissingerP.T.CooksR.G., “Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues”, Proc. Natl. Acad. Sci. USA105, 18120–18125 (2008). doi: 10.1073/pnas.0801066105
17.
KauppilaT.J.TalatyN.KuuranneT.KotiahoT.KostiainenR.CooksR.G., “Rapid analysis of metabolites and drugs of abuse from urine samples by desorption electrospray ionization-mass spectrometry”, Analyst132, 868–875 (2007). doi: 10.1039/b703524a
18.
HuangG.ChenH.ZhangX.CooksR.G.OuyangZ., “Rapid screening of anabolic steroids in urine by reactive desorption electrospray ionization”, Anal. Chem.79, 8327–8332 (2007). doi: 10.1021/ac0711079
19.
LeutholdL.A.MandscheffJ.-F.FathiM.GiroudC.AugsburgerM.VaresioE.HopfgartnerG., “Desorption electrospray ionization mass spectrometry: Direct toxicological screening and analysis of illicit ecstasy tablets”, Rapid Commun. Mass Spectrom.20, 103–110 (2006). doi: 10.1002/rcm.2280
20.
RancV.HavlicekV.BednarP.LemrK., “Desorption electrospray: A modern tool for organic surface analysis”, Chem. Listy101, 524–529 (2007).
21.
TaoW.A.ZhangD.WangF.ThomasP.D.CooksR.G., “Kinetic resolution of D,L-amino acids based on gas-phase dissociation of copper(II) complexes”, Anal. Chem.71, 4427–4429 (1999). doi: 10.1021/ac990530h
22.
TaoW.A.ZhangD.NikolaevE.N.CooksR.G., “Copper(II)-assisted enantiomeric analysis of D,L-amino acids using the kinetic method: Chiral recognition and quantification in the gas phase”, J. Am. Chem. Soc.122, 10598–10609 (2000). doi: 10.1021/ja000127o
23.
TaoW.A.GozzoF.C.CooksR.G., “Mass spectrometric quantitation of chiral drugs by the kinetic method”, Anal. Chem.73, 1692–1698 (2001). doi: 10.1021/ac001150v
24.
ZhangD.TaoW.A.CooksR.G., “Chiral resolution of D- and L-amino acids by tandem mass spectrometry of Ni(II)-bound trimeric complexes”, Int. J. Mass Spectrom.204, 159–169 (2001). doi: 10.1016/S1387-3806(00)00330-4
Compendium of Pharmaceuticals and Specialties 2008.The Canadian Drug Reference for Health Professionals, Canadian Pharmaceutical Assn., Canada (2007).
27.
HammanM.A.ThompsonG.A.HallS.D., “Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C”, Biochem. Pharmacol.54, 33–41 (1997). doi: 10.1016/S0006-2952(97)00143-3
28.
The 2008 prohibited list international standard, The world anti-doping code, World anti-doping agency (2007).
29.
AugustiD.V.AugustiR., “Determination of the enantiomeric composition of ibuprofen solutions via a rapid and sensitive mass spectrometry method”, Tetrahedron-Asymmetry16, 1881–1885 (2005). doi: 10.1016/j.tetasy.2005.04.005
30.
WoitallaD., “Relevance of plasma level determination of l-DOPA and 3-O-methyldopa in Parkinson's disease”, Aktuelle Neurol.25, S279–S281 (1998). doi: 10.1055/s-2007-1017745
31.
GarriottJ.C.SimmonsL.M.PoklisA.MackellM.A., “Five cases of fatal overdose from caffeine-containing look-alike drugs”, J. Anal. Toxicol.9, 141–143 (1985).
32.
RancV.HavlicekV.BednarP.LemrK., “Magnesium interference in phenylalanine enantiomeric discrimination by the kinetic method”, Int. J. Mass Spectrom., in press (2008). doi: 10.1016/j.ijms.2008.09.009
33.
LaskaE.M.SunshineA.MerreroI.OlsonN.SiegelC.McCormickN., “The correlation between blood-levels of ibuprofen and clinical analgesic response”, Clin. Pharmacol. Ther.40, 1–7 (1986).
